Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Several reasons have been proposed as explanations why so many S. aureus vaccines have failed in clinical trials. Clearly, the organism has a battery of virulence factors which may require a multipronged approach and neutralizing just a single mechanism with a specific mAb may not suffice.
There are currently a total of 6 beta-lactam + beta-lactamase inhibitor combinations in clinical trials. It will be a steep learning curve for the pharma reps (and physicians) to understand the resistance classifications, the confusing ESBL definitions, the CRE nomenclature, and how this all matters in clinical practice, on the Continue reading What is the “Niche” for Ceftolozane / Tazobactam?
At a still earlier stage of development, we found some exciting anti-pseudomonal compounds. First, there is BAL-30072, a sulfactam-derivative. It has an interesting dual MoA as it works not only as a traditional B-lactam but also as an Fe-chelator blocking bacteria from accessing this essential nutrient [i]. It has very good anti-pseudomonas Continue reading Fighting P. aeruginosa (Part II)